Aliases & Classifications for 47,xyy

MalaCards integrated aliases for 47,xyy:

Name: 47,xyy 74
Xyy Syndrome 74 52 25 58
Double Y Syndrome 52 58 29
47,xyy Syndrome 52 25 58
47, Xyy Syndrome 52 71
Xyy Karyotype 52 25
Yy Syndrome 52 25
Y Disomy 52 58
Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome 71
Jacob's Syndrome 25
Jacobs Syndrome 52
Disomy Y 52
Double Y 52

Characteristics:

Orphanet epidemiological data:

58
47,xyy syndrome
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Developmental anomalies during embryogenesis


Summaries for 47,xyy

Genetics Home Reference : 25 47,XYY syndrome is characterized by an extra copy of the Y chromosome in each of a male's cells. Although many males with this condition are taller than average, the chromosomal change sometimes causes no unusual physical features. Most males with 47,XYY syndrome have normal production of the male sex hormone testosterone and normal sexual development, and they are usually able to father children. 47,XYY syndrome is associated with an increased risk of learning disabilities and delayed development of speech and language skills. Affected boys can have delayed development of motor skills (such as sitting and walking) or weak muscle tone (hypotonia). Other signs and symptoms of this condition include hand tremors or other involuntary movements (motor tics), seizures, and asthma. Males with 47,XYY syndrome have an increased risk of behavioral, social, and emotional difficulties compared with their unaffected peers. These problems include attention-deficit/hyperactivity disorder (ADHD); depression; anxiety; and autism spectrum disorder, which is a group of developmental conditions that affect communication and social interaction. Physical features related to 47,XYY syndrome can include increased belly fat, a large head (macrocephaly), unusually large teeth (macrodontia), flat feet (pes planus), fifth fingers that curve inward (clinodactyly), widely spaced eyes (ocular hypertelorism), and abnormal side-to-side curvature of the spine (scoliosis). These characteristics vary widely among affected boys and men.

MalaCards based summary : 47,xyy, also known as xyy syndrome, is related to turner syndrome and camptodactyly-arthropathy-coxa vara-pericarditis syndrome. An important gene associated with 47,xyy is IGFBP3 (Insulin Like Growth Factor Binding Protein 3). The drugs Metformin and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and lung, and related phenotypes are malar flattening and low-set ears

NIH Rare Diseases : 52 47, XYY syndrome is a syndrome (group of signs and symptoms) that affects males. For some males with this syndrome, signs and symptoms are barely noticeable. For others, signs and symptoms may include learning disabilities , speech delay , low muscle tone (hypotonia ), and being taller than expected. 47, XYY syndrome is caused by having an extra copy of the Y chromosome in every cell of the body. The syndrome is usually not inherited . Diagnosis can be made based on prenatal tests, or it may occur during childhood or adulthood if a male has signs or symptoms of the disease. Management may include special education as well as intervention or therapies for developmental delays .

Wikipedia : 74 XYY syndrome is a genetic condition in which a male has an extra Y chromosome. Symptoms are usually few.... more...

Related Diseases for 47,xyy

Diseases related to 47,xyy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 turner syndrome 28.8 SRY IGFBP3
2 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 11.6
3 creutzfeldt-jakob disease 11.2
4 47, xxy 10.6
5 azoospermia 10.3
6 tooth size 10.3
7 infertility 10.3
8 autism spectrum disorder 10.2
9 hypogonadotropic hypogonadism 10.2
10 male infertility 10.2
11 hypogonadism 10.2
12 hypogonadotropism 10.2
13 tremor 10.2
14 hair whorl 10.1
15 attention deficit-hyperactivity disorder 10.1
16 hypertelorism 10.1
17 down syndrome 10.1
18 autism 10.1
19 cryptorchidism, unilateral or bilateral 10.1
20 oligospermia 10.1
21 gonadal dysgenesis 10.1
22 learning disability 10.1
23 hypotonia 10.1
24 chromosomal triplication 10.1
25 coloboma of macula 10.0
26 radioulnar synostosis 10.0
27 microcephaly 10.0
28 synostosis 10.0
29 lipoid congenital adrenal hyperplasia 10.0
30 constricting bands, congenital 10.0
31 brachydactyly 10.0
32 oligohydramnios 10.0
33 agammaglobulinemia 10.0
34 tic disorder 10.0
35 olfactory neuroblastoma 10.0
36 neuroblastoma 10.0
37 pulmonary embolism 10.0
38 neurofibromatosis, type ii 10.0
39 elastosis perforans serpiginosa 10.0
40 nondisjunction 10.0
41 noonan syndrome 1 10.0
42 schizophrenia 10.0
43 chromosome 2q35 duplication syndrome 10.0
44 syndactyly, type iii 10.0
45 hydrops fetalis, nonimmune 10.0
46 hypogonadism, male 10.0
47 taurodontism 10.0
48 testes, rudimentary 10.0
49 46,xx sex reversal 1 10.0
50 pituitary adenoma, prolactin-secreting 10.0

Graphical network of the top 20 diseases related to 47,xyy:



Diseases related to 47,xyy

Symptoms & Phenotypes for 47,xyy

Human phenotypes related to 47,xyy:

58 31 (show all 34)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 malar flattening 58 31 hallmark (90%) Very frequent (99-80%) HP:0000272
2 low-set ears 58 31 hallmark (90%) Very frequent (99-80%) HP:0000369
3 delayed speech and language development 58 31 hallmark (90%) Very frequent (99-80%) HP:0000750
4 motor delay 58 31 hallmark (90%) Very frequent (99-80%) HP:0001270
5 tall stature 58 31 hallmark (90%) Very frequent (99-80%) HP:0000098
6 macrocephaly 58 31 frequent (33%) Frequent (79-30%) HP:0000256
7 hypertelorism 58 31 frequent (33%) Frequent (79-30%) HP:0000316
8 intellectual disability 58 31 frequent (33%) Frequent (79-30%) HP:0001249
9 neonatal hypotonia 58 31 frequent (33%) Frequent (79-30%) HP:0001319
10 attention deficit hyperactivity disorder 58 31 frequent (33%) Frequent (79-30%) HP:0007018
11 specific learning disability 58 31 frequent (33%) Frequent (79-30%) HP:0001328
12 impaired social interactions 58 31 frequent (33%) Frequent (79-30%) HP:0000735
13 asthma 58 31 frequent (33%) Frequent (79-30%) HP:0002099
14 impulsivity 58 31 frequent (33%) Frequent (79-30%) HP:0100710
15 congenital stationary night blindness 58 31 frequent (33%) Frequent (79-30%) HP:0007642
16 finger clinodactyly 58 31 frequent (33%) Frequent (79-30%) HP:0040019
17 seizures 58 31 occasional (7.5%) Occasional (29-5%) HP:0001250
18 hydrocephalus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000238
19 macroorchidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000053
20 cryptorchidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000028
21 increased circulating gonadotropin level 58 31 occasional (7.5%) Occasional (29-5%) HP:0000837
22 hypospadias 58 31 occasional (7.5%) Occasional (29-5%) HP:0000047
23 micropenis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000054
24 abnormality of brainstem morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0002363
25 azoospermia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000027
26 oligospermia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000798
27 male infertility 58 31 occasional (7.5%) Occasional (29-5%) HP:0003251
28 dysgenesis of the cerebellar vermis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002195
29 cerebellar dysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0007033
30 increased serum testosterone level 58 31 occasional (7.5%) Occasional (29-5%) HP:0030088
31 varicocele 58 31 occasional (7.5%) Occasional (29-5%) HP:0012871
32 behavioral abnormality 58 Frequent (79-30%)
33 hyperactivity 58 Frequent (79-30%)
34 autistic behavior 58 Occasional (29-5%)

GenomeRNAi Phenotypes related to 47,xyy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.62 IGFBP3 SRY

Drugs & Therapeutics for 47,xyy

Drugs for 47,xyy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 815)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
3
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
4
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
9
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
10
Gliclazide Approved Phase 4 21187-98-4 3475
11
Glyburide Approved Phase 4 10238-21-8 3488
12
Glimepiride Approved Phase 4 93479-97-1 3476
13
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
14
Racepinephrine Approved Phase 4 329-65-7 838
15
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
16
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
17
Histamine Approved, Investigational Phase 4 51-45-6 774
18
Insulin glargine Approved Phase 4 160337-95-1
19
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
20
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
21
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
22
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
23
Lixisenatide Approved Phase 4 320367-13-3
24
Haloperidol Approved Phase 4 52-86-8 3559
25
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
26
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
27
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
28
Abciximab Approved Phase 4 143653-53-6
29
Morphine Approved, Investigational Phase 4 57-27-2 5288826
30
Ribavirin Approved Phase 4 36791-04-5 37542
31
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
32
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
33
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
34
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
35
Remifentanil Approved Phase 4 132875-61-7 60815
36
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
37
Ethanol Approved Phase 4 64-17-5 702
38
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
39
Phenylephrine Approved Phase 4 59-42-7 6041
40
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
41
Adenosine Approved, Investigational Phase 4 58-61-7 60961
42
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
43
Norepinephrine Approved Phase 4 51-41-2 439260
44
Pseudoephedrine Approved Phase 4 90-82-4 7028
45
Ephedrine Approved Phase 4 299-42-3 9294
46
Ondansetron Approved Phase 4 99614-02-5 4595
47
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
48
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
49
Timolol Approved Phase 4 26839-75-8 33624 5478
50
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549

Interventional clinical trials:

(show top 50) (show all 1044)
# Name Status NCT ID Phase Drugs
1 Clinical Trial Program of a Medical Instrument Product Unknown status NCT01157455 Phase 4 Aspirin;Clopidogrel;Heparin or Bivalirudin
2 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
3 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
4 Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-mediated Allergy to Beta-lactams Unknown status NCT01159379 Phase 4 ertapenem
5 Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial Unknown status NCT02615366 Phase 4 Tranexamic Acid;Placebo
6 Pulpal Blood Flow With the Use of Intra-nasal Anesthetic: a Randomized Double-blind Crossover Study Unknown status NCT03368391 Phase 4 tetracaine HCl and oxymetazoline HCL;2% Lidocaine with 1:100,000 epinephrine;3% Mepivacaine with 1:100,000 epinephrine;saline intranasal;saline infiltration
7 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
8 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
9 Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS Completed NCT03644212 Phase 4 Vitamin D3
10 Phase 4 Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric Asthma in a Hospital in Bogotá Completed NCT01333800 Phase 4 Beclomethasone;Ciclesonide
11 A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule Completed NCT01349829 Phase 4
12 Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori Completed NCT02776371 Phase 4 Modified non-clarithromycin triple therapy;Sequential therapy
13 Study of the Effect of Calcifediol Supplementation on Left Ventricular Function in Cardiopathic Patients Undergoing Major Orthopedic Surgery. Completed NCT03403933 Phase 4 Didrogyl
14 A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus Completed NCT02200991 Phase 4 LIXISENATIDE AVE0010;Sitagliptin;Insulin glargine HOE901
15 Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol IM Injection for Treatment of Acute Psychotic Agitation in Schizophrenia Completed NCT00859872 Phase 4 risperidone oral solution;haloperidol
16 Reveal® XT Performance Trial Completed NCT00680927 Phase 4
17 Respiratory Muscle Stretching in Patients With Chronic Obstructive Pulmonary Disease Submitted a Pulmonary Rehabilitation Program Completed NCT00935181 Phase 4
18 Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention.(Molecole di Adesione Nella Sindrome Coronarica Acuta Completed NCT01757457 Phase 4 Intracoronary administration of an abciximab bolus during primary PCI;Intravenous administration of an abciximab bolus during primary PCI
19 A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip Completed NCT02155257 Phase 4 Modafinil;Gabapentin;Placebo
20 Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants: a Randomized Controlled Trial Completed NCT03390374 Phase 4 Nystatin Oral
21 The Effect of Prior Short Course Combination Antiretroviral Therapy Administered for the Prevention of Mother-to-Child Transmission (pMTCT) of HIV-1 on Subsequent Treatment Efficacy in Treatment-"Nearly Naive" Participants Completed NCT00442962 Phase 4 Efavirenz;Emtricitabine/Tenofovir disoproxil fumarate
22 Target-controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by Entropy of the Electroencephalogram: Comparison Between Manual Perfusion and Automated Perfusion Completed NCT00391885 Phase 4
23 Chronic Obstructive Pulmonary Disease and Weaning From Mechanical Ventilation in Difficult to Wean Patients; Randomized Prospective Study Completed NCT00355732 Phase 4
24 Prospective Randomized Trial to Evaluate the Efficacy of Donor Preconditioning With Dopamine on Initial Graft Function After Kidney Transplantation Completed NCT00115115 Phase 4 Dopamine infusion to brain dead organ donors
25 A New Strategy Regarding Discontinuation of Dual Antiplatelet; Real Safety and Efficacy of a 3-month Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents Implantation (RESET Trial) Completed NCT01145079 Phase 4
26 Prospective, Randomized Clinical Trial,to Compare Standard Trabeculectomy to the Ex-PRESS Mini Glaucoma Shunt Implantation Under a Scleral Flap in Eyes With Open-Angle Glaucoma Completed NCT00698438 Phase 4
27 The Effects of Melatonin on Elevated Liver Enzymes During Statins Treatment Completed NCT03121521 Phase 4 Melatonin 10 mg;Placebo
28 A Randomized Trial Comparing Daily Atropine Versus Weekend Atropine Completed NCT00094614 Phase 4 Atropine
29 ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial Completed NCT01058980 Phase 4
30 Effect of Aspirin Intake on Awakening Versus at Bedtime on Circadian Rhythm of Platelet Reactivity in Healthy Subjects Completed NCT01900639 Phase 4
31 Comparison of the Effect of Fluoride Remineralizer Gel and Foam: a Randomized Clinical Trial Completed NCT02490592 Phase 4
32 Crystalloid Coload Combined With Variable Rate Phenylephrine Infusion for Prevention of Hypotension During Spinal Anesthesia for Elective Cesarean Delivery vs Crystalloid Coload Alone Completed NCT01378325 Phase 4 Phenylephrine;saline
33 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg and 220 μg Once Daily on Basal Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Children [>=2 to < 12 Years of Age] With Allergic Rhinitis (AR). Completed NCT01154153 Phase 4 Placebo nasal spray;Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ);Placebo nasal spray;Claritin® Syrup
34 Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma Completed NCT03966560 Phase 4 Brimonidine Tartrate;Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops;Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension;Travoprost and Timolol;Bimatoprost and Timolol;Latanoprost
35 Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules Completed NCT02765763 Phase 4 2-Minute Reveal Masque;24/7 Barrier Repair Cream;8-in-1 BioSerum;Null Formula 2-Minute Reveal Masque;Null Formula 24/7 Barrier Repair Cream;Null Formula 8-in-1 BioSerum
36 Patient-controlled Intermittent Epidural Bolus Versus Epidural Infusion for Posterior Spinal Fusion After Adolescent Idiopathic Scoliosis Completed NCT02669004 Phase 4 Intermittent bolus epidural morphine;continuous epidural morphine
37 Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan Completed NCT00495131 Phase 4 Pegylated interferon alfa-2a plus ribavirin;Pegylated interferon alfa-2a plus ribavirin
38 Incontinence & Intimate Partners: Assessing the Contribution of Treatment Completed NCT01559389 Phase 4 Solifenacin
39 Effects of Anemia Correction on Vascular Function, Endothelial Cell Markers and Monocyte Apoptosis in Renal Transplant Recipients Completed NCT00204334 Phase 4 darbopoeitin
40 Impact of Dexmedetomidine on the Incidence of Postoperative Delirium in Patients After Cardiac Surgery: a Randomized, Double-blinded, and Placebo-controlled Clinical Trial Completed NCT02267538 Phase 4 dexmedetomidine hydrochloride for injection;0.9% sodium chloride for injection
41 Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase Ⅳ Clinical Study Completed NCT03001986 Phase 4
42 Prospective, Randomized Clinical Trial of a Silver Eluting Dressing System for Prevention of Lower Extremity Revascularization Wound Complications Completed NCT01229358 Phase 4
43 Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial Completed NCT02760069 Phase 4 Inhaled isopropyl alcohol;Oral ondansetron;Inhaled normal saline;Oral placebo
44 Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial Completed NCT00914095 Phase 4 methylphenidate;placebo
45 Effects of Eplerenone on Left Ventricular Hypertrophy in Patients With Resistant Hypertension and Obstructive Sleep Apnoea Completed NCT03186742 Phase 4 Eplerenone 50 mg Tab
46 Midazolam With Meperidine and Dexmedetomidine vs Midazolam With Meperidine for Sedation During ERCP Completed NCT01404689 Phase 4 Dexmedetomidine
47 Nicotine Replacement Therapy Added to Cognitive Behavioral Therapy for Smoking Cessation in Patients With Major Mental Illness Completed NCT00320723 Phase 4 bupropion, transdermal nicotine patch
48 A Randomized Trial of Deep Neuromuscular Blockade Reversed With Sugammadex Versus Moderate Neuromuscular Block Reversed With Neostigmine, on Postoperative Quality of Recovery Completed NCT03034577 Phase 4 Sugammadex;Neostigmine
49 Phase 4 Study of Primary Use of the Vacuum Assisted Laparostomy in Treatment of Severe Peritonitis Completed NCT01531543 Phase 4
50 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet

Search NIH Clinical Center for 47,xyy

Genetic Tests for 47,xyy

Genetic tests related to 47,xyy:

# Genetic test Affiliating Genes
1 Double Y Syndrome 29

Anatomical Context for 47,xyy

MalaCards organs/tissues related to 47,xyy:

40
Breast, Testes, Lung, Liver, Bone, Heart, Brain

Publications for 47,xyy

Articles related to 47,xyy:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Clinical aspects of infertile 47,XYY patients: a retrospective study. 61 52
28715980 2019
2
Oral, physical, and behavioral aspects of patient with chromosome 47, XYY syndrome. 61 52
26381641 2015
3
Positive effects of early androgen therapy on the behavioral phenotype of boys with 47,XXY. 61 52
25939399 2015
4
Valorization of olive mill leaves through ultrasound-assisted extraction. 61
31982857 2020
5
Sequence data describing the fungal community in a tropical quartzite soil. 61
31993470 2020
6
6-OH-BDE-47 exposure-induced Parkinson's disease pathology in Sprague Dawley rat. 61
32000351 2020
7
Soil concentrations and soil-air exchange of polycyclic aromatic hydrocarbons in five Asian countries. 61
31822410 2020
8
Direct conversion of untreated cane molasses into butyric acid by engineered Clostridium tyrobutyricum. 61
31958691 2020
9
Food waste from restaurant sector - Characterization for biorefinery approach. 61
31958693 2020
10
Two tiered approaches combining alternative test methods and minimizing the use of reconstructed human cornea-like epithelium tests for the evaluation of eye irritation potency of test chemicals. 61
31648046 2020
11
Retention of polybrominated diphenyl ethers and hydroxylated metabolites in paired human serum and milk in relation to CYP2B6 genotype. 61
31901712 2020
12
Use of human liver and EpiSkin™ S9 subcellular fractions as a screening assays to compare the in vitro hepatic and dermal metabolism of 47 cosmetics-relevant chemicals. 61
31912921 2020
13
FDG PET/CT and MRI in Primary Spinal Cord Glioblastoma. 61
31693607 2020
14
Forensic features, genetic diversity and structure analysis of three Chinese populations using 47 autosomal InDels. 61
31865224 2020
15
Chronic severe pyloric lesions in horses: 47 cases. 61
31390081 2020
16
Is sarcoidosis related to metabolic syndrome and insulin resistance? 61
31250684 2020
17
Pretreatment of polysaccharidic wastes with cellulolytic Aspergillus fumigatus for enhanced production of biohythane in a dual-stage process. 61
31869631 2020
18
Evaluation of sagittal airway dimensions after face mask therapy with rapid maxillary expansion in Class III growing patients. 61
31812840 2020
19
Trisomy 18 in a First-Trimester Fetus with Thoraco-Abdominal Ectopia Cordis. 61
31215820 2020
20
[Therapeatic Efficacy of Decitabine on Low and Moderate-Risk MDS Patients and the Prognostic Factors]. 61
32027279 2020
21
Increased Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a Low-Risk Cohort: Evidence From 47 874 Cases. 61
32008433 2020
22
Novel mutations in SPEF2 causing different defects between flagella and cilia bridge: the phenotypic link between MMAF and PCD. 61
31942643 2020
23
Manual annotation combined with untargeted metabolomics for chemical characterization and discrimination of two major crataegus species based on liquid chromatography quadrupole time-of-flight mass spectrometry. 61
31753484 2020
24
Racial Inequities in Preventable Pregnancy-Related Deaths in Louisiana, 2011-2016. 61
31923055 2020
25
Assessing burden of central line-associated bloodstream infections present on hospital admission. 61
31515099 2020
26
Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors. 61
31724795 2020
27
Lack of orientation selectivity of the heme insertion in murine neuroglobin revealed by resonance Raman spectroscopy. 61
32034988 2020
28
Construction of Ribonuclease-Decorated Artificial Virus-like Capsid by Peptide Self-assembly. 61
31875395 2020
29
N-acetylcysteine and ascorbic acid therapy for acute hepatic injury after hexavalent chromium ingestion. 61
31579951 2020
30
Hard-Sphere Random Close-Packed Au47 Cd2 (TBBT)31 Nanoclusters with a Faradaic Efficiency of Up to 96 % for Electrocatalytic CO2 Reduction to CO. 61
31834651 2020
31
Dual mobility constructs in revision total hip arthroplasty: survivorship analysis in recurrent dislocation versus other indications at three to twelve-year follow-up. 61
31758218 2020
32
Variability of Pneumocystis jirovecii prophylaxis use among pediatric solid organ transplant providers. 61
31713958 2020
33
Impact of forest cover and conservation agriculture on sediment export: A case study in a montane reserve, south-western China. 61
31733551 2020
34
Corrigendum to "The evaluation of the effect of vaginal delivery and aging on anal sphincter anatomy and function" [J. Gynecol. Obstet. Hum. Reprod. 47 (2018): 309-315]. 61
31917261 2020
35
Prevalence of underweight, wasting and stunting among young children with a significant cognitive delay in 47 low-income and middle-income countries. 61
31845425 2020
36
Proceedings of the RAMI Section of Ophthalmology Meeting, Friday 29th November 2019 in the Chartered Accountants House, 47, Pearse Street, Dublin 2. 61
32026237 2020
37
A MIL-47(V) derived hierarchical lasagna-structured V2O3@C hollow microcuboid as an efficient sulfur host for high-performance lithium-sulfur batteries. 61
32040104 2020
38
[Erratum to "How I do … an hematocolpos evacuation and obstructed hemivagina resection" [Gynecol. Obstet. Fertil. Senol. 47 (2019) 884-888]]. 61
31956055 2020
39
The Relationship Between Medication Attitudes and Medication Adherence Behavior in Adults With Bipolar Disorder. 61
31929465 2020
40
Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3. 61
31922425 2020
41
Extrauterine adenomyomas presenting in a 47 year old woman with a previous cesarean section. 61
31872018 2020
42
Chest pressure and dyspnoea in a 47-year-old man. 61
31988249 2020
43
HLA-B*15:47:01 allele with undefined serological equivalent considered as B Blank. 61
31599086 2020
44
Helcococcus kunzii methyltransferase Erm(47) responsible for MLSB resistance is induced by diverse ribosome-targeting antibiotics. 61
31670815 2020
45
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. 61
31821109 2020
46
Trends, Outcomes, and Predictors of Revascularization in Cardiogenic Shock. 61
31784052 2020
47
Changes in aniseikonia of an axial anisometrope at various stages of orthokeratology lens wear. 61
31732264 2020
48
Lymphomas with kidney involvement: the French multicenter retrospective LyKID study. 61
32037948 2020
49
Tumor-specific prognosis of mutation-positive patients with head and neck paragangliomas. 61
32035780 2020
50
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. 61
32024071 2020

Variations for 47,xyy

Expression for 47,xyy

Search GEO for disease gene expression data for 47,xyy.

Pathways for 47,xyy

GO Terms for 47,xyy

Sources for 47,xyy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....